Notch 3 protein, not its gene polymorphism, is associated with the chemotherapy response and prognosis of advanced NSCLC patients

Cellular Physiology and Biochemistry

Volumn 34, Issue 3, 2014, Pages 743-752

  Shi, Chunlei ^a   Qian, Jialin ^a   Ma, Meili ^a   Zhang, Yanwei ^a   Han, Baohui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Chemotherapy; Non small cell lung cancer; NOTCH3; Prognosis

Indexed keywords

CISPLATIN; NOTCH3 RECEPTOR; PLATINUM DERIVATIVE; RETROVIRUS VECTOR; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; NOTCH RECEPTOR; NOTCH3 PROTEIN, HUMAN;

A549 CELL LINE; ADULT; ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMOSENSITIVITY; CLINICAL FEATURE; CYTOTOXICITY ASSAY; DNA POLYMORPHISM; EXPRESSION VECTOR; FEMALE; GENE FREQUENCY; GENETIC TRANSFECTION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MTT ASSAY; NICK END LABELING; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; CARCINOMA, NON-SMALL-CELL LUNG; GENETIC POLYMORPHISM; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTORS, NOTCH;

EID: 84906610573     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000363039     Document Type: Article

References (29)

1. Kosmidis P: Chemotherapy in NSCLC: historical review. Lung Cancer 2002;38:S19-22.
2. Hildebrandt MA, Gu J, Wu X: Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol 2009;5:745-755.
3. Gridelli C, Ferrara C, Del Gaizo F, Guerriero C, Nicolella D, Colantuoni G, Rossi A: Chemotherapy of advanced NSCLC in the elderly. Tumori 2002;88:S143-144.
4. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P: Genome-wide association study of survival in non-small cell lung cancer patients receiving platinumbased chemotherapy. J Natl Cancer Inst 2011;103:817-825.
5. Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK, Song Y: Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol 2011;28:315-321.
6. Hou XW, Son J, Wang Y, Ru YX, Lian Q, Majiti W, Amazouzi A, Zhou YL, Wang PX, Han ZC: Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycininduced cardiomyopathy in rats. Cardiovasc Drugs Ther 2006;20:85-91.
7. Glaysher S, Yiannakis D, Gabriel FG, Johnson P, Polak ME, Knight LA, Goldthorpe Z, Peregrin K, Gyi M, Modi P, Rahamim J, Smith ME, Amer K, Addis B, Poole M, Narayanan A, Gulliford TJ, Andreotti PE, Cree IA: Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC Cancer 2009;9:300.
8. Li D, Zhou Q, Liu Y, Yang Y, Li Q: DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Med Oncol 2012;29:1622-1628.
9. Ehebauer M, Hayward P, Martinez-Arias A: Notch signaling pathway. Sci STKE 2006;2006:cm7.
10. Rose SL: Notch signaling pathway in ovarian cancer. Int J Gynecol Cancer 2009;19:564-566.
11. Brzozowa M, Mielanczyk L, Michalski M, Malinowski L, Kowalczyk-Ziomek G, Helewski K, Harabin-Slowinska M, Wojnicz R: Role of Notch signaling pathway in gastric cancer pathogenesis. Contemp Oncol (Pozn) 2013;17:1-5.
12. Li C, Zhang Y, Lu Y, Cui Z, Yu M, Zhang S, Xue X: Evidence of the cross talk between Wnt and Notch signaling pathways in non-small-cell lung cancer (NSCLC): Notch3-siRNA weakens the effect of LiCl on the cell cycle of NSCLC cell lines. J Cancer Res Clin Oncol 2011;137:771-778.
13. Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, Minna JD, Roberts JR, Carbone DP: Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst 2000;92:1355-1357.
14. Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Olson S, Gonzalez A, Carbone DP, Dang TP: Dominantnegative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res 2005;65:3555-3561.
15. Zheng Y, de la Cruz CC, Sayles LC, Alleyne-Chin C, Vaka D, Knaak TD, Bigos M, Xu Y, Hoang CD, Shrager JB, Fehling HJ, French D, Forrest W, Jiang Z, Carano RA, Barck KH, Jackson EL, Sweet-Cordero EA: A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. Cancer Cell 2013;24:59-74.
16. Park JT, Chen X, Trope CG, Davidson B, Shih Ie M, Wang TL: Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 2010;177:1087-1094.
17. Menon S, Cox HC, Kuwahata M, Quinlan S, MacMillan JC, Haupt LM, Lea RA, Griffiths LR: Association of a Notch 3 gene polymorphism with migraine susceptibility. Cephalalgia 2011;31:264-270.
18. Wu F, Hu N, Li Y, Bian B, Xu G, Zheng Y: Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC. Cell Oncol (Dordr) 2012;35:175-180.
19. Monteiro DR, Zuim PR, Pesqueira AA, Ribeiro Pdo P, Garcia AR: Relationship between anxiety and chronic orofacial pain of temporomandibular disorder in a group of university students. J Prosthodont Res 2011;55:154-158.
20. Roy B, Maksemous N, Smith RA, Menon S, Davies G, Griffiths LR: Two novel mutations and a previously unreported intronic polymorphism in the NOTCH3 gene. Mutat Res 2012;732:3-8.
21. Remmele W, Stegner HE: [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987;8:138-140.
22. Dang L, Fan X, Chaudhry A, Wang M, Gaiano N, Eberhart CG: Notch3 signaling initiates choroid plexus tumor formation. Oncogene 2006;25:487-491.
23. Li L, Zeng H, Hou X, He X, Chen JX: Myocardial injection of apelin-overexpressing bone marrow cells improves cardiac repair via upregulation of Sirt3 after myocardial infarction. PLoS One 2013;8:e71041.
24. Zhang S, Loch AJ, Radtke F, Egan SE, Xu K: Jagged1 is the major regulator of Notch-dependent cell fate in proximal airways. Developmental dynamics : an official publication of the American Association of Anatomists 2013;242:678-686.
25. Ye YZ, Zhang ZH, Fan XY, Xu XL, Chen ML, Chang BW, Zhang YB: Notch3 overexpression associates with poor prognosis in human non-small-cell lung cancer. Med Oncol 2013;30:595.
26. Hou XW, Wang LF, Wang N, Pang D, Hui B, Zhou YL, He X: The G501C polymorphism of oxidized LDL receptor gene [OLR-1] is associated with susceptibility and serum C-reactive protein concentration in Chinese essential hypertensives. Clin Chim Acta 2008;388:200-203.
27. Lee SH, Jeong EG, Yoo NJ, Lee SH: Mutational analysis of NOTCH1, 2, 3 and 4 genes in common solid cancers and acute leukemias. APMIS 2007;115:1357-1363.
28. Maraver A, Fernandez-Marcos PJ, Herranz D, Canamero M, Munoz-Martin M, Gomez-Lopez G, Mulero F, Megias D, Sanchez-Carbayo M, Shen J, Sanchez-Cespedes M, Palomero T, Ferrando A, Serrano M: Therapeutic effect of gamma-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell 2012;22:222-234.
29. Zhang S, Hou X, Zi S, Wang Y, Chen L, Kong B: Polymorphisms of receptor for advanced glycation end products and risk of epithelial ovarian cancer in Chinese patients. Cell Physiol Biochem 2013;31:525-531.